AMGEN INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 315.4 USD | +13.28% |
|
+16.82% | +9.50% |
| 05:45pm | UBS Adjusts Price Target on Amgen to $307 From $284, Maintains Neutral Rating | MT |
| 05:41pm | Deutsche Bank Adjusts Price Target on Amgen to $310 From $285, Hold Rating Maintained | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
278.4
USD
Average target price
304.4
USD
Spread / Average Target
+9.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.50% | 149B | |
| +26.17% | 681B | |
| +21.85% | 556B | |
| -5.21% | 361B | |
| +17.16% | 325B | |
| +4.81% | 285B | |
| +13.57% | 235B | |
| +3.65% | 199B | |
| -11.12% | 189B | |
| -4.08% | 157B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Amgen : Secures FDA Priority Review for Asthma Drug Candidate
